Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients by Liikanen, Ilkka et al.
original article © The American Society of Gene & Cell Therapy
Oncolytic adenoviruses and certain chemotherapeutics 
can induce autophagy and immunogenic cancer cell 
death. We hypothesized that the combination of oncolytic 
adenovirus with low-dose temozolomide (TMZ) is safe, 
effective, and capable of inducing antitumor immune 
responses. Metronomic low-dose cyclophosphamide (CP) 
was added to selectively reduce regulatory T-cells. Pre-
clinically, combination therapy inhibited tumor growth, 
increased autophagy, and triggered immunogenic cell 
death as indicated by elevated calreticulin, adenosine tri-
phosphate (ATP) release, and nuclear protein high-mobility 
group box-1 (HMGB1) secretion. A total of 41 combina-
tion treatments given to 17  chemotherapy-refractory 
cancer patients were well tolerated. We observed anti- 
and proinflammatory cytokine release, evidence of virus 
replication, and induction of neutralizing antibodies. 
Tumor cells showed increased autophagy post-treatment. 
Release of HMGB1 into serum—a possible indicator of 
immune response—increased in 60% of treatments, and 
seemed to correlate with tumor-specific T-cell responses, 
observed in 10/15 cases overall (P = 0.0833). Evidence 
of antitumor efficacy was seen in 67% of evaluable treat-
ments with a trend for increased survival over matched 
controls treated with virus only. In summary, the combi-
nation of oncolytic adenovirus with low-dose TMZ and 
metronomic CP increased tumor cell autophagy, elicited 
antitumor immune responses, and showed promising 
safety and efficacy.
Received 13 September 2012; accepted 19 February 2013; advance online 
publication 2 April 2013. doi:10.1038/mt.2013.51
INTRODUCTION
The cytotoxic mechanism of most anticancer drugs is induction of 
apoptosis, the resistance to which is a distinctive feature of recur-
rent advanced tumors. Emerging evidence indicates that both 
oncolytic adenoviruses and certain chemotherapeutics can induce 
autophagic cell death.1–3 Type II programmed cell death is charac-
terized by increased turnover of cellular organelles leading to cell 
death. Recently, autophagy has been implicated as a prerequisite 
for immunogenic cancer cell death;4,5 a phenomenon useful for 
induction of antitumor immunity.6 It is characterized by exposure 
of calreticulin on the membrane of the dying tumor cell and sub-
sequent release of danger signals such as adenosine triphosphate 
(ATP) and nuclear protein high-mobility group box-1 (HMGB1), 
resulting in activation of nearby dendritic cells.
Temozolomide (TMZ) is an alkylating agent, which has dem-
onstrated antitumor activity in the treatment of, e.g., glioma, 
melanoma, and pituitary cancer. Virus-induced autophagy corre-
lates positively with virus replication and oncolytic cell death,1,2,7 
however, the role of TMZ-induced autophagy remains controver-
sial. As a single agent, TMZ-induced autophagy seems to have a 
cytoprotective role.8 On the other hand, equivalent doses showed 
enhanced cytotoxicity through autophagy when combined with 
thalidomide; a drug proposed to affect the PI3K/Akt/mTOR 
pathway that plays a role in autophagy regulation.9 Accordingly, 
autophagic cell death was recently found necessary for the anti-
tumor effects of the TMZ/radiotherapy combination.10 These data 
are compatible with the theory that baseline autophagy is essen-
tially a survival process, whereas mortal autophagic flux—most 
easily achieved by a combination treatment—can be exploited 
in anticancer therapy. Both aspects have been studied in trials: 
autophagy inhibitor chloroquine has shown moderate efficacy in 
a phase III clinical trial;11 meanwhile, the combination of thalido-
mide and TMZ has been studied in phase II trials with promising 
results.12,13
We hypothesized that the combination of oncolytic adeno-
virus and low-dose pulse of TMZ can lead to improved efficacy 
via induction of autophagy and antitumor immune responses. 
In addition, since it is well-established that regulatory T-cells are 
inhibitory for tumor immunotherapy,14 we used low-dose metro-
nomic cyclophosphamide (CP) for their selective reduction.15,16
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RESULTS
TMZ and CP increase efficacy of oncolytic adenovirus 
and promote immunogenic cancer cell death in vitro
Combination of oncolytic adenovirus Ad5/3-D24-GMCSF and 
TMZ was tested in prostate cancer PC3-MM2 and breast cancer 
MDA-MB-436 cell lines (Figure 1a and Supplementary Figure S1) 
together with 4-hydroperoxycyclophosphamide (4-HPCP), an active 
metabolite of the prodrug CP. The triple combination increased cell 
killing over chemotherapeutic agents and virus alone (P < 0.01, 
P  <  0.05, respectively). Combination of virus with either chemo-
therapeutic agent alone also increased cell killing (Supplementary 
Figure S1). In PC3-MM2 cells, combination of TMZ with oncolytic 
adenovirus indicated strong synergism as assessed by the Chou–
Talalay method,17 whereas 4-HPCP failed to show clear synergis-
tic effect with virus in vitro (Supplementary Figure S2), which is 
compatible with its proposed immunological role. Nevertheless, the 
triple combination was synergistic at the most relevant “high frac-
tion-affected levels” (the right edge of the graph).17
Immunogenic cell death is emerging as a potentially crucial 
step between innate and adaptive antitumor immune responses, 
and could be partially responsible for the efficacy of some chemo-
therapeutics.18 Cancer cells undergoing immunogenic cell death 
first expose calreticulin on their outer plasma membrane, and 
next release HMGB1 and ATP to the tumor microenvironment. 
The triple combination of virus, TMZ, and 4-HPCP resulted in 
significant increase of calreticulin-positive cells followed by ATP 
and HMGB1 release when compared with control cells (P < 0.05, 
P < 0.001, P < 0.05, respectively) (Figure 1b). Of note, there were 
no signs of cytopathic effect at this time, suggesting release of dan-
ger signals before cell death and lysis.
Increased autophagy coincides with tumor growth 
inhibition in combination-treated prostate tumors  
in vivo
Prostate cancer xenograft-bearing mice received Ad5/3-D24-
GMCSF virus or growth medium twice intratumorally followed 
by intraperitoneal injections of TMZ (10 mg/kg) or saline, and CP 
(20 mg/kg) or saline (Figure 1c). Virus combined to TMZ showed 
enhanced tumor growth inhibition compared with  control (P < 
0.05), and the effect was further enhanced when CP was added 
(P < 0.01). As expected, subtherapeutic low-dose administration 
of both TMZ and CP alone did not inhibit tumor growth.
Electron microscopy on PC3-MM2 tumors revealed autoph-
agic vacuoles in combination- and virus-treated tumor cells 
(Figure 1d). Of note, autophagic flux in the combination-treated 
cells appeared more pronounced since it was accompanied with 
a decrease in the numbers of mitochondria, accumulation of 
late autolysosomes (with degraded cytosolic material inside), 
and disruption of the plasma membrane. Virus progeny was 
observed inside some of the autophagic tumor cells and adjacent 
extracellular space. To further confirm these results, immuno-
histochemistry for microtubule-associated protein light chain 3 
(LC3), an autophagosomal marker, was performed (Figure 1e). 
Combination-treated tumors presented a significantly higher 
frequency of LC3 punctate-positive cells compared with control 
tumors (Supplementary Figure S3), and were characterized by 
several autophagy-rich areas inside the tumors.
Combination treatments are well tolerated in 
patients, with fewer adverse reactions when TMZ is 
administered after oncolytic adenovirus
A total of 17 patients with advanced solid tumors progressing 
after conventional therapies were treated with oncolytic adeno-
viruses (Supplementary Tables S1 and 2). Group 1 received 
low-dose TMZ (100 mg/day) for 5 days before virus, group 2 
for 5–7 days before and 2 weeks after the virus, and group 3 
for 7–10 days after viral treatment. In addition, low-dose met-
ronomic oral CP (50 mg/day) was started 1 week before virus 
treatment and continued until progression16 (Supplementary 
Table S2).
Treatments were well tolerated with mostly grade 1–2 adverse 
reactions (ARs) (Table 1). We observed grade 3 lymphopenia in 
37% of all treatments, and one patient had a grade 4 decrease in 
leukocyte counts. Lymphopenia may in fact reflect redistribution 
of lymphocyte subsets to tumors following virus injection and 
therefore may not be an actual “adverse” reaction but rather a phe-
nomenon contributing to efficacy.19,20 When comparing to patient 
treatments with oncolytic adenoviruses and CP,16 adding low-dose 
pulse of TMZ, as used here, does not appear to increase ARs; only 
grade 2 nausea seemed more common when TMZ was added (22 
versus 11%, not significant).
Most ARs were spontaneously self-limiting. However, one 
potentially treatment-related event led to patient hospitaliza-
tion and was therefore classified as a serious adverse event: grade 
3 ileus was observed in a cholangiocarcinoma patient (Y166). 
Pediatric patient U157 experienced grade 3 liver transaminase 
increase and grade 2 hemoglobin decrease, and N21 had grade 3 
abdominal pain and thrombocytopenia, which were alleviated by 
blood transfusions and antibiotics without need for hospitaliza-
tion. There were no grade 4–5 clinical ARs.
Interestingly, the laboratory AR profile favored patients receiv-
ing TMZ after the virus treatment (Table 1; in parenthesis): grade 
1–2 ARs were recorded in 94 and 83% of treatments in group 1 
as opposed to only 75 and 50% in group 3 (P < 0.05). A similar 
trend was also observed in grade 3–4 ARs. Given the adenovirus-
mediated hepatotoxicity frequently seen in mice, liver enzyme ele-
vations were of particular interest. Transaminase increases were 
more common when TMZ was given before virus, as opposed to 
only after virus (P = 0.06; Table 1).
Pro- and anti-inflammatory cytokines transiently 
increase when TMZ is administered before virus
Interleukin-6 and -10 showed a transient increase at day 1 post-
treatment in the overall patient series (P < 0.05 and P < 0.0001, 
respectively). When patients were grouped according to TMZ 
dosing, however, the highest inflammatory cytokine changes, and 
the only statistically significant ones, were observed in patients 
receiving TMZ before virus (group 1, Supplementary Figure S4). 
This finding is in concordance with the frequency of ARs post-
treatment (Table 1).
Treatment efficacy
Twenty-one individual treatments were evaluable by imaging, 
and nine by “tumor markers” present in serum. Efficacy was 
evaluated by comparing pre- and post-treatment computed 
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Figure 1 Immunogenic cell killing and increased autophagy coincide with tumor growth inhibition in oncolytic adenovirus, temozolomide 
(TMZ)- and cyclophosphamide-treated prostate cancer. (a) Cell-killing efficacy of combination treatments. Ten virus particles (VP)/cell of onco-
lytic adenovirus combined with TMZ (c1 = 0.035, c2 = 0.105 mg/ml) and 4-HPCP (c1 = 0.003125, c2 = 0.00525 mg/ml) resulted in superior cell 
killing over chemotherapeutic agents or virus alone (P < 0.01, P < 0.05, respectively). (b) Immunogenicity of cell death. Combination treatment with 
100 VP/cell of Ad5/3-D24-GMCSF virus, TMZ (0.0025 mg/ml), and 4-HPCP (0.00208 mg/ml) resulted in significant increase in calreticulin-positive 
PC3-MM2 cells, and extracellular ATP and HMGB1 levels, as compared with untreated cells. Treatment with TMZ and 4-HPCP increased calreticulin-
positive cells and ATP release, whereas oncolytic virus seemed to induce mostly ATP and HMGB1 release, but lacked significant induction of others. 
Data in a,b are representative of three independent experiments. (c) Efficacy of combination therapy in vivo. Nude/NMRI mice bearing subcutane-
ous PC3-MM2 xenografts were treated intratumorally with Ad5/3-D24-GMCSF virus or growth medium (black arrows) followed by intraperitoneal 
injections of TMZ or saline (gray arrows), and cyclophosphamide (CP) or saline (white arrowheads). Virus + TMZ, and virus + TMZ + CP treatments 
significantly inhibited tumor growth as compared with phosphate-buffered saline (PBS) control. (d,e) Induction of autophagy after combination 
therapy in vivo. (d) Electron microscopy on fixed tumor tissues revealed large tumor cells with enlarged nuclei, abundant mitochondria, ribosomes, 
and glycogen deposits (gray vacuoles). Autophagosomes and autolysosomes were only found in virus-, virus + TMZ-, and virus + TMZ + CP-treated 
tumor cells (black arrowheads). VPs were observed inside some of the autophagic cells (white arrowheads). (e) Tumors were assessed by immuno-
histochemistry for LC3, a membrane-bound protein accumulating on late autophagosomes. Punctate staining pattern was considered indicative of 
autophagy (black arrowheads; ×40 original magnification). Error bars represent the mean ± SEM. All studies, n = 3–6; *P < 0.05; **P < 0.01; ***P < 
0.001; unpaired t-tests in a,b; one-way analysis of variance repeated measures in c. 4-HPCP, 4-hydroperoxycyclophosphamide; ATP, adenosine 
 triphosphate; GMCSF, granulocyte-macrophage colony-stimulating factor; HMGB1, high-mobility group box-1.
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Table 1 Adverse reactions (AR) shown as a percentage of all treatments 
 Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Laboratory
 Hemoglobin decrease 34 (44; 14; 31) 22 (11; 57; 19) 0 0
 Leukopenia 15 (22; 14; 6) 34 (39; 71; 13) 2 (6; 0; 0) 0
 Lymphopenia 10 (11; 0; 13) 39 (44; 29; 38) 37 (28; 71; 31) 2 (6; 0; 0)
 Granulocytopenia 5 (6; 0; 13) 5 (0; 0; 13) 2 (0; 14; 0) 0
 Liver transaminase 27 (22; 71; 13) 10 (22; 0; 0) 2 (0; 14; 0) 0
 Thrombocytopenia 27 (22; 57; 19) 2 (0; 0; 6) 2 (6; 0; 0) 0
 Elevated INR 12 (17; 0; 13) 0 0 0
 Hyperbilirubinemia 5 (11; 0; 0) 0 0 0
 Hyponatremia 24 (33; 29; 13) — 2 (6; 0; 0) 0
 Hypokalemia 22 (22; 43; 13) — 2 (0; 0; 6) 0
 Creatinine increase 2 (6; 0; 0) 5 (6; 0; 6) 2 (0; 14; 0) 0
Any laboratory AR 88 (94; 100; 75) 71 (83; 86; 50) 49 (44; 86; 38) 2 (6; 0; 0)
Pain
 Injection site 15 (17; 29; 6) 5 (6; 14; 0) 0 0
 Abdominal 7 (6; 29; 0) 5 (0; 14; 6) 2 (6; 0; 0) 0
 Back/sides 2 (6; 0; 0) 20 (17; 57; 6) 0 0
 Chest 5 (6; 14; 0) 7 (6; 29; 0) 0 0
 Head 5 (0; 0; 13) 5 (0; 14; 6) 0 0
 Other 17 (17; 14; 19) 5 (0; 0; 13) 0 0
Gastrointestinal
 Diarrhea 10 (6; 0; 19) 7 (0; 0; 19) 0 0
 Constipation 5 (11; 0; 0) 2 (0; 0; 6) 0 0
 Bloating 5 (0; 29; 0) 0 0 0
 Dysphagia 0 5 (0; 0; 13) 0 0
 Loss of appetite 5 (0; 14; 6) 5 (11; 0; 0) 0 0
 Nausea 32 (33; 0; 44) 22 (22; 43; 13) 0 0
 Vomiting 12 (17; 29; 0) 2 (6; 0; 0) 0 0
 Ileus 0 0 2 (6; 0; 0)a 0
Respiratory and cardiovascular system
 Dyspnea 2 (6; 0; 0) 12 (11; 14; 13) 0 0
 Cough 12 (17; 14; 6) 7 (6; 14; 6) 0 0
 Hypotension 10 (11; 14; 6) 2 (6; 0; 0) 0 0
General
 Fever 41 (33; 43; 50) 32 (28; 43; 31) 2 (6; 0; 0) 0
 Chills 41 (28; 29; 63) 15 (11; 29; 13) 0 0
 Fatigue 29 (28; 57; 19) 29 (33; 43; 19) 0 0
 Flu-like symptoms 7 (6; 14; 6) 2 (6; 0; 0) 0 0
 Sweating 2 (6; 0; 0) 2 (6; 0; 0) 0 0
 Edema/swelling 15 (11; 43; 6) 2 (0; 0; 6) 0 0
 Anxiety 2 (0; 0; 6) 2 (0; 0; 6) 0 0
Any clinical AR 93 (100; 100; 81) 83 (72; 100; 88) 7 (17; 0; 0) 0
Any AR 100 (100; 100; 100) 95 (94; 100; 94) 54 (56; 86; 38) 2 (6; 0; 0)
Percentages in parentheses represent adverse reactions (ARs) in groups 1, 2, and 3, respectively. Follow-up time for ARs was 28 days after virus treatment. Grade 1–2 
ARs seen in 1–2 cases are not shown. Note that the majority of grade 3–4 ARs were “lymphopenia”, which may reflect redistribution of lymphocyte subsets from blood 
to tumors as predicted for a potent immunotherapeutic.20 Lymphocytes were manually counted utilizing leukocyte values and automated estimation of lymphocyte 
percentages by a clinical grade cell counter. Group 1: temozolomide before virus; Group 2: temozolomide before and after virus; Group 3: temozolomide after virus.
INR, international normalized ratio.
aSerious adverse event leading to patient hospitalization, discussed in text.
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Table 2 Patient follow-up and clinical response 
Patient 
code Type of cancer Virus
Temozolomide,  
100 mg/day (days)
Imaging/marker  
response Survival (days)
Group 1: Temozolomide (100 mg/day) before viral treatment
N21 Neuroblastoma ICOVIR-7 3 US, mPR 298
H148 Pancreatic ICOVIR-7 5 mMR 63
S149 Endometrial sarcoma ICOVIR-7 5 SD (−5%) 951
Ad5/3-D24-GMCSF 5 MR (−15%)
Ad5-D24-GMCSF 5 SD (+1%)a
Ad5-RGD-D24-GMCSF 5 SD (+1%)a
Ad5/3-D24-GMCSF 5 SD (+1%)a, mMR
Y166 Cholangio carcinoma Ad5/3-D24-GMCSF 5 47
N127 Head and neck Ad5/3-D24-GMCSF 5 118
M3 Hepatocellular carcinoma Ad5-RGD-D24-GMCSF 5 105
C156 Colon Ad5-RGD-D24-GMCSF 5 PD (+45%)a, mPD 269
Ad5-RGD-D24-GMCSF 5 PD (+45%)a, mPD
Ad5-RGD-D24-GMCSF 5 PD (+45%)a, mPD
M50 Mesothelioma Ad5-RGD-D24-GMCSF 5 SD (+8%) 462
Ad5-D24-GMCSF 1 PD (+34%)
K75 Lung adenocarcinoma Ad5-D24-GMCSF 5 123
S119b Sarcoma Ad5-D24-GMCSF 5 SD (+1%) 1,459c
Ad5/3-D24-GMCSF 5 SD (+12%)
Group 2: Temozolomide (100 mg/day) before and after viral treatment
C145 Colon Ad5/3-D24-GMCSF 5 + 14 PD (+45%), mPD 140
Ad5-D24-GMCSF 5 + 14 PD (+35%), mPD
M137 Mesothelioma Ad5-RGD-D24-GMCSF 7 + 14 SD (−4%) 779
Ad5-D24-GMCSF 7 + 14 SD (+19%)
U157 Wilms’ tumor Ad5/3-D24-GMCSF 5 + 0 147
Ad5-D24-GMCSF 0 + 17
T19 Medullary thyroid Ad5-D24-GMCSF 5 + 15 SD (+7%), mSD 565
Group 3: Temozolomide (100 mg/day) after viral treatment
K152 Lung adenocarcinoma ICOVIR-7 7 PD (+35%)a 283
Ad5/3-Cox2L-D24 7 PD (+35%)a
Ad5-D24-GMCSF 7 PD (+35%)a
Ad5-RGD-D24-GMCSF 7 PD (+48%)a
Ad5/3-D24-GMCSF 7 PD (+48%)a
Ad3-hTERT-E1A 7 PD (+48%)a
S153 Synovial sarcoma Ad5/3-D24-GMCSF 10 51
S171 MFH sarcoma ICOVIR-7 10 SD (−2%) 553
Ad5/3-D24-GMCSF 10 SD (−0%)
Ad3-hTERT-E1A 10 SD (−1%)
Ad5/3-hTERT-E1A-CD40L 10 PD (+31%)a
Ad5/3-hTERT-E1A-CD40L 10 PD (+31%)a
Ad5/3-hTERT-E1A-CD40L 10 PD (+31%)a
S119b Sarcoma Ad3-hTERT-E1A 7 SMD (+26%)a 1,459c
ICOVIR-7 7 SMD (+26%)a
Ad5-D24-GMCSF 7 SMD (+26%)a
Percentages in parentheses indicate exact change in the sum of tumor diameters. Tumor markers (mPR, mMR, mSD, mPD), when available, were scored with the 
same percentages.
GMCSF, granulocyte-macrophage colony-stimulating factor; MFH, malignant fibrous histiocytoma; MR, minor response; PD, progressive disease; PR, partial response; 
SD, stable disease; SMD, stable metabolic disease; US, response in ultrasound imaging.
aSerial treatment, imaging was performed after the third treatment. bPatient received treatments according to group 1 and later group 3. cAlive at the end of follow-up.
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tomography, magnetic resonance imaging or positron emis-
sion tomography scans. One treatment response was graded as 
minor response, 12 as stable disease (SD), and seven as progres-
sive disease (Table 2).
An endometrial sarcoma patient S149, receiving TMZ 
according to group 1, benefited from the first round of combi-
nation  treatment with SD and received four further treatment 
rounds  (Table 2). Interestingly, the second treatment with Ad5/3-
D24-GMCSF virus together with TMZ and CP resulted in 15% 
decrease (minor response) of the intra-abdominal lesions near 
the pancreas (Figure 2a–c). A serial combination treatment 6 
months later resulted in SD and she survived for 951 days which is 
unusual for patients with metastatic and progressing chemother-
apy-refractory grade 3 endometrial sarcoma.
Similarly, a mesothelioma patient M137 who received TMZ 
according to group 2, benefited from two rounds of combination 
treatment with sustained SD and an unexpectedly long survival of 
779 days, again unusual for mesothelioma progressing after che-
motherapy. Clinical benefit was suggested also by a decrease in 
pleural effusion. In group 3, patient S171 with malignant fibrous 
histiocytoma progressing at baseline, received multiple rounds of 
treatment with continued evidence of disease control and survival 
of 553 days. Pediatric patient N21 (group 1) with neuroblastoma 
had a partial response as assessed by tumor markers and clinical 
response by ultrasound imaging.
To conclude, objective evidence of efficacy, SD or better in 
patients progressing before therapy, was seen in 67% of radiologi-
cally evaluable treatments and in 4/9 treatments evaluable with 
tumor markers measured from blood.
Presence of viral genomes and neutralizing 
antibodies in patient serum
Since injected virus is rapidly cleared from the circulation, extended 
presence of virus genomes in serum is indicative of virus replica-
tion.21 We detected viral DNA in serum samples of 28/38 evaluable 
treatment cycles, with prolonged circulating viral DNA in 14 cases, 
suggesting effective virus replication (Supplementary Table S3). 
The longest timepoint for detectable virus in circulation was day 
74 for pediatric patient N21. The highest titer of 611,235 virus par-
ticle (VP)/ml was observed in patient C156 after the third treatment 
with Ad5-RGD-D24-GMCSF virus and TMZ. Interestingly, this 
adenoviral capsid-specific neutralizing antibody titer had gradually 
increased to 1,024 (Supplementary Table S4), but did not seem to 
limit virus replication. Overall neutralizing antibodies elevated to a 
median of 4,096 by 1 month post-treatment. Patients who had not 
received prior virotherapy showed significantly lower neutralizing 
antibody titers at baseline and at 1 week after the first treatment (P 
< 0.05, both), increasing to the overall median by 1 month.
Autophagy induction in patient ascites tumor cells 
after combination treatment
We had access to pre- and post-treatment ascites samples of two 
pancreatic carcinoma patients, who were combination-treated with 
oncolytic adenovirus, metronomic CP, and TMZ for 7 days after 
the virus, and assessed them for autophagy by LC3 immunohisto-
chemistry. A clear increase in LC3 punctate pattern-positive tumor 
cells was observed 6 days after virus treatment (H339; Figure 2d), 
and still at day 21 post-treatment (H333; Figure 2d), indicative of 
autophagy induction in patients after combination therapy.
Figure 2 Computed tomography of an endometrial sarcoma patient, and autophagy induction in patient ascites tumor cells after com-
bination treatment. (a–c) Metastases near the pancreas (white arrowheads) (a) before treatment, and injected target lesions (b) after the first 
round of oncolytic virotherapy together with metronomic cyclophosphamide (CP), and temozolomide (TMZ) for 5 days before virus resulted 
in 5% decrease in tumor diameters. (c) Second treatment with Ad5/3-D24-GMCSF, metronomic CP, and TMZ for 5 days before virus resulted 
in 15% reduction. (d) Pre- and post-treatment ascites cells of two pancreatic carcinoma patients treated with Ad5/3-hTERT-E1A-CD40L virus, 
metronomic CP, and TMZ for 7 days after virus were assessed for autophagy by LC3 immunohistochemistry. Higher frequency of LC3 punctate-
positive tumor cells (black arrowheads) was observed in post-treatment samples (right column) indicative of autophagy induction. No clinical 
information was available for these patients and therefore they are not included in the other display items. GMCSF, granulocyte-macrophage 
colony-stimulating factor.
H339 H339
H333 H333
Before 6 Days after
Before10 Weeks
5 Weeks
0 Weeks
a
b
c
d
21 Days after
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Adenovirus- and tumor-specific T-cell responses in 
combination-treated cancer patients
Increase of tumor-specific T-cells in blood indicates activation 
of the adaptive immunity, whereas decrease has been proposed 
compatible with trafficking of T-cells from the blood to tumors;19,20 
no change could indicate immunological anergy. Cases were classi-
fied as “induction” or “decrease/trafficking” when the change was 
>20% over the baseline (Figure 3a). A total of 10 stimulated T-cells 
Figure 3 Antitumor T-cells are stimulated by combination treatments and correlate with HMGB1 secretion into serum; a potential marker 
of immunogenic cell death. (a) Peripheral blood mononuclear cells (PBMCs) were pulsed with peptide mix for adenovirus serotype 5 (Ad5) penton 
(gray bars) or for survivin (black bars), a ubiquitous tumor-associated antigen, and assessed for T-cell activation by interferon-γ ELISPOT analysis. 
Unspecific T-cell responses were also observed, which might include other tumor epitope-directed T-cells (white bars). Induction of antitumor T-cells 
was observed in eight cases (open triangles) and decrease/trafficking in two cases (closed triangles). Adenovirus-specific T-cell activations were seen in 
10/15 cases (open circles). Patient S119 received temozolomide (TMZ) according to group 1 and later group 3; for convenience, both are shown in 
the group 3 row. The adenoviral peptide mix was for serotype 3 in the latter case (Ad3 hexon). (b) Quantitative determination of HMGB1 in patient 
serum was performed by enzyme-linked immunosorbent assay. Significant elevations of the immunogenic signal over baseline were observed in 60% 
of patients (*P < 0.05; **P < 0.01; unpaired t-test). HMGB1 titer change correlated with antitumor T-cell responses (triangle markers) in 8/9 evaluable 
cases. The only exception was patient C145, who showed a high antitumor T-cell induction at week 4 post-treatment, but lacked HMGB1 elevation 
at the time (triangle in parenthesis). The nine evaluable cases were S149, N127, M3, M50, C145, K152, and S171 2nd, S119 1st, and S119 2nd treat-
ment rounds; Patient C156 had absolute T-cell counts below the limit of reliable detection and was therefore excluded from statistical analyses. Error 
bars represent the mean ± SEM, n = 3 per timepoint. 1st, initial treatment rounds; 2nd, later treatment rounds; Group 1, TMZ before virus; Group 2, 
TMZ before and after virus; Group 3, TMZ after virus; HMGB1, high-mobility group box-1; SFC, spot-forming colonies.
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were considered the lower limit of reliable detection. It should be 
noted that cells were analyzed without prior stimulation and expan-
sion ex vivo, and thus the counts represent actual numbers present 
in blood. Altogether 8/15 patient treatments resulted in induction 
of tumor-specific T-cell responses while two cases were compatible 
with trafficking of cells from blood to target tissues.
Immunogenic cell death signal HMGB1 elevates 
in patient serum after combination treatment and 
correlates with tumor-specific T-cell responses
Our preclinical data suggested that cancer cell death elicited by 
 oncolytic adenovirus together with TMZ and CP is immuno-
genic (Figure 1b). Thus, we hypothesized that HMGB1 in patient 
serum might correlate with antitumor T-cell activation; 60% of 
patients showed a significant elevation of HMGB1 (Figure 3b). 
Interestingly, the highest increase (2.5-fold) was seen in patient 
S119, who had  prolonged disease control and the longest ongo-
ing survival. Similarly, there was a gradual activation of antitumor 
T-cells by 9 weeks. It is intriguing to speculate that these two phe-
nomena might be linked. Notably, in 8/9 evaluable cases, there was 
a correlation between HMGB1 titer change and antitumor T-cell 
response  overtime (P = 0.0833), suggesting a candidate  predictive 
marker for antitumor immune responses, although further stud-
ies are needed in this regard.
Survival
Overall survival of combination-treated patients was compared 
with nonrandomized matched control patients treated similarly 
in the same Advanced Therapy Access Program, but without 
TMZ (Figure 4). Median survival in combination-treated patients 
was 269 days versus 170 days in virus-only treated controls (not 
significant). At the end of follow-up, one patient (S119) was still 
alive with 1,459 days and ongoing.
T-cell response or HMGB1 release did not correlate with ther-
apeutic efficacy as assessed by imaging and/or tumor markers. 
However, Fisher’s exact test suggested that there was a correlation 
between HMGB1 response and survival (P = 0.0119). Six patients 
with HMGB1 increase had a survival higher than (or equal to) the 
median of the patient series, whereas three patients with decrease 
or no change in HMGB1 levels had shorter than median survival. 
When compared with matched controls, patients with HMGB1 
increase had improved survival (P = 0.0476, Fisher’s exact test), a 
provocative finding considering the lack of a significant difference 
in the overall population. Although tantalizing, we feel that these 
are quite preliminary data and should be studied further.
DISCUSSION
Oncolytic adenoviruses are emerging as a tool for treatment of 
advanced solid tumors incurable with current therapies. Although 
safety has been excellent, the efficacy of single agent treatment 
leaves room for improvement.22 Based on preclinical and clinical 
data, combination with chemotherapy has the potential to further 
enhance antitumor activity of oncolytic virotherapy synergisti-
cally,23–25 often without an increase in side effects.
Combinations of an oncolytic virus and alkylating agents 
have undergone preclinical testing with favorable results.26 TMZ 
significantly improved survival of mice when combined with 
oncolytic adenoviruses Ad5-D24-RGD and ICOVIR-5 in glioma 
xenografts,27 and we saw enhanced tumor growth inhibition in 
prostate cancer xenografts using Ad5/3-D24-GMCSF. One poorly 
understood aspect of anticancer therapies in general is the mech-
anism of tumor cell death. “Silent” apoptotic cancer cell death–
induced by most chemotherapeutics–can lead to immunological 
tolerance.28 In contrast, emerging evidence suggests that immu-
nogenic cancer cell death is useful or even necessary for induction 
of antitumor immunity.18 This phenomenon has been proposed 
dependent on autophagy,4,5 in conjunction with exposure of cal-
reticulin on the plasma membrane and release of danger signals, 
ATP and nuclear protein HMGB1. Both oncolytic adenoviruses 
and TMZ have been shown to induce autophagic cell death in 
preclinical experiments.2,8,29 Our data suggest that their combina-
tion increases autophagy and immunogenic cell killing in both 
preclinical systems and in patients, possibly in conjunction with 
antitumor T-cell activations observed in humans.
HMGB1 can be released from malignant cells in the context 
of necrotic cell death.30 Preclinical studies indicate that HMGB1 
levels may help in differentiating between physiological silent 
apoptotic cell death and pathological immunogenic necrotic, or 
autophagic, cell death.31 Our data suggests that combination treat-
ment results in HMGB1 release in association with autophagic 
cell death. A mechanistic feature could involve oncolysis, possi-
bly enhanced by TMZ-mediated induction of autophagy, allow-
ing leakage of HMGB1 to the systemic circulation and disclosing 
the current immunogenic state of the tumor. Accordingly, we 
noticed correlations between serum HMGB1 titer changes and 
antitumor T-cell responses in 8/9 evaluable treatments. This asso-
ciation should be studied further to determine whether HMGB1 
serum level can be used as immunological response marker for 
Figure 4 Survival of combination-treated patients is increased over 
matched nonrandomized control patients. Overall survival of 17 onco-
lytic adenovirus, temozolomide (TMZ)- and cyclophosphamide (CP)-
treated patients was analyzed by the Kaplan–Meier method. Matching 
control patients (n = 17) treated without TMZ were selected retrospec-
tively from the same patient cohort taking into account putative prog-
nostic  factors. Median survival in the combination-treated (Virus + TMZ) 
patients was 269 days versus 170 days in virus-treated controls. One 
combination-treated patient was alive at the end of follow-up with a 
survival of 1,459 days.
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cancer therapeutics in general and oncolytic viruses in particular. 
Provocatively, and requiring further study, HMGB1 increase post-
treatment correlated with overall survival.
Interestingly, we observed tumor- and adenovirus-specific 
immune responses that seemed to be enhanced in some patients 
by repeated combination treatment. Toll-like receptors 2 and 9 
have previously been reported as the main pattern-recognition 
receptors for adenovirus.32,33 Evidence suggests that toll-like 
receptor 2 is specifically recruited to the phagosomes and may 
be directly involved in the internalization of pathogens or their 
parts by cells.34 In addition to non-self patterns, toll-like recep-
tor 2 complexes are capable of detecting altered self-patterns, dis-
played by e.g., necrotic cells.35 Therefore, pathogen recognition by 
immune cells may be enhanced also by autophagy-modulating 
agents such as TMZ.
It is noteworthy that 67% of the evaluable combination treat-
ments resulted in disease control, taking into account that all 
patients were refractory to, and progressing after, available con-
ventional treatments. Although our patient series is too small to 
make definitive conclusions, especially mesenchymal cancers are 
interesting since 80% of the instances of disease control (focusing 
on radiology alone: 12/13 treatments = 92%) were seen in patients 
with sarcoma or mesothelioma.
In conclusion, autophagy-inducing immunogenic combina-
tion treatment with oncolytic adenovirus, low-dose pulse of TMZ, 
and low-dose metronomic CP, given to patients with tumors 
refractory to conventional therapies, resulted in disease control in 
67% of treatments. Safety was good throughout and liver enzyme 
elevations suggested that the low-dose TMZ pulse is optimally 
delivered after virus injections (group 3). The translational pilot 
investigation reported here justifies further testing and suggests 
that clinical trials are warranted to further study the potency of 
oncolytic adenoviruses with autophagy-inducing agents such as 
TMZ.
MATERIALS AND METHODS
Cell culture and viability assays. Prostate cancer PC3-MM2 and breast 
cancer MDA-MB-436 cell lines (American Type Culture Collection, 
Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum, and maintained at humidified 
37 °C and 5% CO2. Cells in triplicates were treated with Ad5/3-D24-
GMCSF virus, TMZ (MSD, Espoo, Finland), and/or 4-HPCP (D-18864; 
NIOMECH, Bielefeld, Germany) in 100 μl of 2% DMEM, adding 100 μl of 
10% DMEM 24 hours later. Cell viability was measured using CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI). 
To determine synergism, the interactions between Ad5/3-D24-GMCSF 
virus, TMZ, and 4-HPCP in PC3-MM2 cell line were analyzed with the 
Chou–Talalay median effect principle17 using the CompuSyn software 
(ComboSyn, Paramus, NJ).
Immunogenicity of cell death
Calreticulin exposure. PC3-MM2 cells in triplicates were infected with 100 
VP/cell, and 12 hours post-infection treated with TMZ (c = 0.0025 mg/
ml) and/or 4-HPCP (c = 0.00208 mg/ml) in 5% DMEM. Cells were har-
vested 24 hours later and stained with anti-calreticulin antibody (ab2907, 
1:1,000; Abcam, Cambridge, UK) for 40 minutes at 4 °C and Alexa-Fluor 
488 IgG as secondary antibody (A21206, 1:100; Invitrogen, Carlsbad, CA) 
for 40 minutes at 4 °C, and analyzed by FACSAria flow cytometer (BD 
Biosciences, San Diego, CA). FlowJo software (Tree Star, Ashland, OR) was 
used for data analysis.
Extracellular ATP and HMGB1. Cells in triplicates were treated as 
above. Supernatant was collected after 36 hours and analyzed with ATP 
Determination Kit (A22066; Molecular Probes, Invitrogen, Paisley, UK) 
and HMGB1 ELISA Kit (ST51011; IBL International, Hamburg, Germany) 
according to the manufacturer’s recommendations, using normal range 
procedure.
Animal experiments. Three to four weeks old male nude/NMRI mice 
(Taconic, Ejby, Denmark) were xenografted with 4 × 106 PC3-MM2 cells 
subcutaneously in both flanks, randomized into six groups, and a week 
later treated twice intratumorally with 2 × 1010 VP of Ad5/3-D24-GMCSF 
virus or growth medium. Mice received intraperitoneal injections of TMZ 
(10 mg/kg in NaCl) or saline for five consecutive days, and CP (20 mg/kg 
in NaCl) or saline on days 0, 4, and 7. Tumor volume follow-up (n = 6 
tumors) was continued until day 12. The health of the mice was followed 
daily and mice were killed according to the humane end-point guide-
lines. Animal experiments were approved by the Experimental Animal 
Committee of the University of Helsinki and the Provincial Government 
of Southern Finland.
Electron microscopy. PC3-MM2 xenografts were removed immediately 
after euthanizing the mice and fixed with 2.5% glutaraldehyde in 0.1 mol/l 
phosphate buffer (pH 7.4) and post-fixed with 2% osmium tetroxide for 
1 hour, dehydrated in series of ethanol, and embedded in LX-112 resin. 
Ultra-thin sections were cut at 50–60 nm, stained with uranyl acetate 
and lead citrate in Leica EMstain automatic stainer (Leica microsystems, 
Wetzlar, Germany) according to the manufacturer’s recommendations. 
Imaging was performed by Jeol JEM-1400 electron microscope (Jeol, 
Tokyo, Japan) using 80 kV accelerating voltage. Digital microphotographs 
were captured by Olympus-Sis Morada digital camera (Olympus, Münster, 
Germany).
Immunohistochemistry analysis. Mouse PC3-MM2 xenografts harvested 
on day 12 post-treatment were fixed with 4% paraformaldehyde, embed-
ded in paraffin, and stained with rabbit polyclonal LC3 isoform B anti-
body (ab48394; Abcam). Sections were boiled for 15 minutes at 98 °C in 
10 mmol/l citrate buffer (pH 6) and treated with 3% hydrogen peroxide 
for 5 minutes. LC3B antibody (1:1,500 in Dako Antibody Diluent (S0809; 
Dako, Carpinteria, CA)) was applied for 60 minutes. Sections were washed 
and treated with LSAB+ System-HRP Kit (K0679; Dako) according to 
the manufacturer’s instructions, and counterstained with hematoxylin. 
Number of LC3 punctate-positive cells (>3 dots/cell) per 40x visual field 
(n = 5) was calculated under a Leica DM LB microscope, and digital images 
were captured using an Olympus DP50 color camera and Studio Lite 1.0 
software (Pixera, San Jose, CA). For patient ascites samples, cells were fixed 
with methanol and assessed for immunohistochemistry as above; LC3B 
primary antibody (1:1,500) was applied for 120 minutes.
Patients. Before virotherapy, all patients had metastatic solid tumors pro-
gressing after conventional therapies with WHO performance score ≤3 
and no major organ function deficiencies (Supplementary Table S1). 
Other exclusion criteria were applied as previously reported.36 All patients 
gave a written informed consent and the principles of treatments includ-
ing possible side effects were explained verbally and in writing. Treatments 
were given in the context of an Advanced Therapy Access Program (ATAP) 
regulated by Finnish Medicines Agency (FIMEA) as determined by 
EU/1394/2007, and performed according to Good Clinical Practice and the 
Helsinki Declaration of World Medical Association. Patient sample analy-
ses are approved by the local Ethics Committee (HUS 62/13/03/02/2013).
Adenoviruses. All adenoviruses used in this study have been published.37–48 
ICOVIR-7 and Ad5-D24-RGD-GMCSF are based on serotype 5  adeno-
virus with a capsid modification of RGD-4C motif in the HI-loop of the 
fiber.37,38 Ad5/3-Cox2L-D24, Ad5/3-D24-GMCSF, and Ad5/3-hTERT-
E1A-CD40L are serotype 5 adenoviruses capsid-modified with adenovirus 
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serotype 3 knob.39–41 In addition, Ad5-D24-GMCSF, Ad5/3-D24-GMCSF, 
and Ad5-RGD-D24-GMCSF viruses express granulocyte-macrophage 
colony-stimulating factor (GMCSF), and Ad5/3-hTERT-E1A-CD40L 
expresses human CD40 ligand.41–43 Ad5/3-hTERT-E1A-CD40L and Ad3-
hTERT-E1A (a serotype 3 adenovirus) have E1A under human telomerase 
promoter.44 The tumor selectivity is based on a 24-base pair deletion in the 
retinoblastoma binding site of E1A or tumor-specific promoter, thus target-
ing replication to cancer cells. Previously published luciferase-expressing 
viruses Ad5lucRGD,45 Ad5Luc1,46 Ad5/3Luc1,47 and Ad3Luc148 were used 
in neutralizing antibody assays. Virus production was done according to 
the current good manufacturing practice by Oncos Therapeutics. (Helsinki, 
Finland). For preclinical studies, Ad5/3-D24-GMCSF was amplified on 
A549 cells (American Type Culture Collection) and purified on double 
cesium chloride gradients. The VP concentration (1.6 × 1013 VP/ml) was 
measured spectrophotometrically and the amount of infectious particles 
was determined by a standard TCID50 assay on 293 cells (Microbix, Toronto, 
Ontario, Canada). The ratio of VP/infectious units was 18.
Patient treatments. Patients received oncolytic adenovirus on day 0 intra-
tumorally (primary tumor and/or any metastasis) in ultrasound guidance, 
when applicable. In case of intraperitoneal or intrapleural disease, the “intra-
tumoral” injection was performed intracavitary. Some patients received 
virus also intravenously, as published previously.40 Patients received oral low-
dose TMZ according to different dosing schedules (Supplementary Table 
S2): TMZ was initially administered before the virus (group 1), but due to 
observations of liver transaminase increase (Table 1), we aimed to assess 
whether combination therapy was better tolerated when TMZ was adminis-
tered before and after (group 2), or only after (group 3) the virus treatment.
In the absence of contraindications (95% of treatments), patients 
received concomitant low-dose CP to reduce regulatory T-cells,16 which was 
administered either metronomically per oral, as a bolus infusion together 
with virus injection, or as combination of these (Supplementary Table 
S2). Oral CP was initiated 1 week before virus treatment and continued 
until progression. Intravenous infusion of CP has been shown to induce 
similar immunological effects.16 Chemotherapeutic doses were adjusted 
for pediatric patients (Supplementary Table S2). In ATAP, each treatment 
is individually optimized for each patient, and thus new information 
regarding the experimental therapy may have supported multiple treatment 
rounds, use of a different virus, or alternate dosing schedule, as in the case 
of patient S119 (Table 2 and Supplementary Table S2).
Surveillance. Patients were monitored for 24 hours in the hospital and 
4 weeks as outpatients, with clinical status and laboratory data recorded 
intermittently. ARs were reported according to Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0 criteria (Table 1). Pre-existing 
symptoms were not listed unless worsened, in which case they were scored 
according to final severity, not change. All grade 3–5 ARs were classified as 
either being serious adverse events (resulting in hospitalization, malforma-
tion, life-threatening condition, or death of patient), or not.
Tumor assessment by contrast-enhanced computed tomography, 
positron emission tomography-computed tomography, or magnetic 
resonance imaging scanning was performed before and 3–6 weeks 
after the treatment. In case of a serial treatment, which comprises three 
consecutive treatment cycles at 1-month intervals, radiological evaluation 
was performed before and after the complete treatment series (Table 2). 
RECIST v1.1 criteria49 were applied to overall disease status including 
injected and noninjected lesions: complete response; partial response 
(≥30% reduction in the sum of tumor diameters); SD (no response, no 
progression); progressive disease (≥20% increase or appearance of new 
metastatic lesions). In addition, minor response (10–29% reduction) was 
used as an indicator of cases where biological activity might be present. 
Tumor markers, if elevated at baseline, were recorded and evaluated using 
the same percentages by comparing baseline to the best/worst response 
(Table 2).
Patient follow-up started on the virus injection day of the first TMZ-
combined treatment. Matching control patients treated without TMZ were 
selected retrospectively among the same ATAP cohort according to the 
known prognostic factors in descending order of relevance (percentage 
of successful matches in parenthesis): tumor type (100%), concomitant 
low-dose CP administration (yes/no 94%), exact same round of virus 
treatment (71%), treatment with the same oncolytic adenovirus (52%), 
WHO performance status at baseline (48%). In addition, treatment dose 
was matched. Self-controls were not allowed.
Detection of viral DNA in serum. Total DNA from serum was extracted 
using carrier DNA (polydeoxyadenylic acid; Roche, Mannheim, 
Germany) with QIAamp DNA mini kit (Qiagen, Hilden, Germany), 
eluted in 60 μl nuclease-free water and DNA concentration was mea-
sured by spectrophotometry. Detection of serotype 5 adenoviruses 
was done as described earlier.41,43,50 For Ad3-hTERT-E1A virus, PCR 
amplification was based on a forward primer (5′-GTTTACGTG 
GAGGTTTCGATT-3′) targeting the wild-type genome in front of the E1A 
promoter area, and a reverse primer (5′-GACAGCGCAGCGATCA-3′) 
overlapping with the hTERT insertion specific to Ad3-hTERT-E1A virus. The 
TAMRA probe (5′-TCCGCGTACGGTGTCAAAGTTCTG-3′) attaches 
to wild-type genome between the primers (Oligomer, Helsinki, Finland). 
The real-time PCR conditions for each 25 μl reaction tested in duplicates 
were as follows: 2X LightCycler480 Probes Master Mix (Roche), 800 
nmol/l forward and 1,000 nmol/l reverse primer, 200 nmol/l probe, and 9.5 
μl extracted DNA. Cycling conditions (Light Cycler 480; Roche): 2 minutes 
at 50 °C, 10 minutes at 95 °C, 50 cycles of 10 seconds at 95 °C and 1 minute 
at 60 °C, 10 minutes at 40 °C. TaqMan exogenous internal positive control 
reagents (Applied Biosystems, Carlsbad, CA) were used in the same PCR 
runs to test the presence of PCR inhibitors. The viral loads in serum were 
calculated using a regression standard curve based on serial dilutions of 
adenoviruses in normal human serum (1 × 109–1 × 101 VP/ml). The limit 
of quantification for the assay was set to 500 VP/ml of serum.
Cytokine analysis. Cytokine analysis was performed using BD Cytometric 
Bead Array Human Soluble Protein Master Buffer Kit for serum samples 
and BD Cytometric Bead Array Human IL-6, IL-8, IL-10, TNF-α, and 
GM-CSF Flex sets (BD Biosciences, San Diego, CA) according to the 
manufacturer’s instructions. BD FACSArray Bioanalyzer, BD FACS Array 
System software, and FCAP Array v1.0.2 software (BD Biosciences) were 
used for data analysis.
Neutralizing antibody titer determination. Neutralizing antibody titer 
using identical matching of adenovirus capsid (Ad5lucRGD,45 Ad5Luc1,46 
Ad5/3Luc1,47 and Ad3Luc148) was done as described earlier.41 The neutral-
izing titer was determined as the lowest degree of dilution that blocked 
gene transfer >80%.
Adenovirus- and tumor-specific T-cell responses. Interferon-γ ELISPOT 
was performed as previously described.41 Peripheral blood mononuclear 
cells were stimulated with the human adenovirus serotype 5 penton or 
serotype 3 hexon peptide pool (HAdV-5 or HAdV-3; ProImmune, Oxford, 
UK) to detect adenovirus-specific responses, and with a tumor-associated 
BIRC5 PONAB peptide Survivin (ProImmune, Oxford, UK) to detect 
tumor- specific antigen responses. ELISPOT assays were performed with-
out pre- stimulation or clonal expansion of peripheral blood mononuclear 
cells and thus results indicate the actual frequency of these cells in blood.
HMGB1 in patient serum. HMGB1 concentration in patient serum 
was measured in triplicates using HMGB1 ELISA Kit (ST51011; IBL 
International) according to the manufacturer’s instructions, using high-
sensitive range protocol. Hemolytic serum samples were considered 
unsuitable for testing.
Statistical analysis. Preclinical data were analyzed using two-tailed t-tests 
and one-way analysis of variance (SPSS v18.0; SPSS, Chicago, IL). ARs 
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were analyzed with two-tailed t-test for independent samples. Serum cyto-
kine levels were analyzed with one-way analysis of variance on log-trans-
formed data with Tukey’s multiple comparison test. Neutralizing antibody 
and HMGB1 serum data were analyzed with two-tailed t-tests, and corre-
lations between HMGB1 and T-cell responses, and HMGB1 response and 
survival with two-tailed Fisher’s exact test (n = 9, both). Patient survival 
data was plotted into a Kaplan–Meier curve and groups (n = 17 + 17) were 
compared pairwise with log-rank test.
SUPPLEMENTARY MATERIAL
Figure S1. Oncolytic adenovirus combined with temozolomide or 
the active metabolite of cyclophosphamide increases cancer cell kill-
ing in vitro.
Figure S2. Interactions between oncolytic adenovirus, temozolo-
mide, and cyclophosphamide show synergism in vitro.
Figure S3. Combination of oncolytic adenovirus, temozolomide, 
and cyclophosphamide induces autophagy in vivo.
Figure S4. Changes in cytokines in patients receiving oncolytic ad-
enovirus, temozolomide, and cyclophosphamide.
Table S1. Patient demographics.
Table S2. Characteristics of patients and treatment protocols.
Table S3. Viral genomes present in patient serum.
Table S4. Neutralizing antibody titers in patient serum.
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